DoW Peer Reviewed Medical, Clinical Trial Award
Closed Posted
- Opportunity number
- HT942526PRMRPCTA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement, Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command seeks applicants for the Fiscal Year 2026 Peer Reviewed Medical Research Program Clinical Trial Award, with a full application deadline of September 22, 2026 and a pre-application deadline of July 23, 2026. Applicant eligibility is unrestricted; extramural and intramural U.S. Department of War organizations, foreign and domestic entities, and for-profit and nonprofit organizations are eligible. Principal investigators must be independent researchers (e.g., Assistant Professor or equivalent) affiliated with eligible organizations, with no more than one FY26 PRMRP application per investigator. No cost share is required.
The program expects to allot approximately $94.5 million to fund approximately 9 awards. Award ceilings are $800,000 for planning phases, $6 million for Funding Level 1 (phase 0, phase 1, or non-phased trials with fewer than 100 participants), $10 million for Funding Level 2 (phase 2 or non-phased trials with fewer than 300 participants), and $20 million for Funding Level 3 (phase 3 or non-phased trials with more than 300 participants). Maximum period of performance is 4 years for clinical trials and 12 months for planning phases.
Applications must address congressionally directed FY26 PRMRP topic areas and strategic goals. The program supports two application categories: Clinical Trial Only (for trials with existing regulatory approvals, which may receive priority) and Clinical Trial with Planning Phase (for final regulatory activities and planning prior to trial initiation). Planning phases cannot support finalizing interventions or animal studies; all preclinical work must be completed before the award start date. Funded trials must register on ClinicalTrials.gov, post informed consent forms on public federal websites, and submit quarterly and annual technical progress reports with enrollment reporting by sex, race, and ethnicity.
Applications undergo two-tier review: peer review evaluating clinical impact, research strategy, recruitment and retention plans, regulatory strategy, and budget justification, followed by programmatic review for funding recommendations based on peer ratings and PRMRP relevance. The program operates under CFDA 12.420, Military Medical Research and Development.
Synopsis
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have significant impact on the treatment and management of a disease or condition addressed in one of the congressionally directed FY26 PRMRP topic areas and FY26 PRMRP strategic goals.
Distinctive Features: Must support a clinical trial. Supports two different application categories, based on the phase of planning for the clinical trial: Clinical Trial Only or Clinical Trial with Planning Phase. The Clinical Trial with Planning Phase option is intended to support the final phase of regulatory activities and planning activities that are necessary to be completed prior to initiation of the clinical trial. The planning phase cannot be used to finalize the intervention or support animal studies. Applications that already have regulatory approvals in place and are submitting to the Clinical Trial Only option may be prioritized over those requesting the Planning Phase option. Animal studies are not supported. Studies must complete all preclinical empirical laboratory work prior to the award start date.
Supports three funding levels, each offered with and without a Planning Phase:
Funding Level 1: Supports phase 0 or phase 1 clinical trials or non-phased trials with fewer than 100 participants.
Funding Level 2: Supports phase 2 clinical trials or non-phased trials with fewer than 300 participants.
Funding Level 3: Supports phase 3 clinical trials or non-phased trials with more than 300 participants.
Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $94.5M to fund approximately 9 Clinical Trial Award applications with total cost caps of $800,000 for the planning phase of a Clinical Trial with Planning Phase, $6M for Funding Level 1, $10M for Funding Level 2, and $20M for Funding Level 3 per award. The maximum period of performance is 4 years for the clinical trial, and 12 months for the planning phase. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
Files
| File | Type | Posted |
|---|---|---|
| PKG00292724.pdf | ||
| HT942526PRMRPCTA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity